Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP1LC3B | Q9GZQ8 | 6/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 3/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795165 | 0.83 | MAP1LC3B (0.68) | MAP1LC3BMEN1KMT2ALMNAHPGD | |
| SCHEMBL21774000 | 0.81 | MAP1LC3B (0.62) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL21821646 | 0.81 | MAP1LC3B (0.62) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL1780317 | 0.80 | MAP1LC3B (1.00) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL26522054 | 0.80 | MAP1LC3B (0.61) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL21821730 | 0.80 | MAP1LC3B (0.61) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL21821899 | 0.79 | MAP1LC3B (0.60) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL21821737 | 0.79 | MAP1LC3B (0.60) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL21821664 | 0.79 | MAP1LC3B (0.60) | MAP1LC3BMEN1KMT2AGAAMAPT | |
| SCHEMBL29581567 | 0.79 | MAP1LC3B (0.60) | MAP1LC3BMEN1KMT2AGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632903-B1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | ATG7, ATG4A, MLST8 | MAP1LC3B 19/4885MEN1 3270/4885KMT2A 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.